Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87637 refers to a diagnostic procedure that utilizes a multiplex amplified probe technique for the detection of specific infectious agents, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza virus types A and B, and respiratory syncytial virus (RSV). This advanced testing method is particularly significant in the context of respiratory illnesses, as it allows for the simultaneous identification of multiple viruses from a single patient sample. The procedure is designed to detect even minute quantities of viral genetic material, which is crucial for accurate diagnosis, especially when the presence of the virus is low. The process begins with the collection of a respiratory sample, which can be obtained through various methods such as swabbing the nose or throat, or through more invasive techniques like bronchoalveolar lavage. Once the sample is collected, it undergoes a series of chemical treatments to isolate the RNA, which is then reverse transcribed into DNA, as the amplification process requires DNA. The use of oligonucleotide probes and primers, which are tagged with fluorescent markers, allows for the specific targeting and amplification of the viral DNA. This amplification is achieved through a series of cycles in a real-time reverse transcription-polymerase chain reaction (RT-PCR) machine, where the amount of DNA doubles with each cycle. The fluorescent markers provide real-time feedback on the amplification process, enabling the detection of the virus when a certain fluorescence threshold is reached. This method not only confirms the presence of the virus but also aids in assessing the severity of the disease based on the number of cycles required to achieve this confirmation. Overall, this procedure plays a critical role in the management of respiratory illnesses, guiding treatment decisions and public health measures.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87637 is indicated for the detection of specific viral infections in patients presenting with respiratory symptoms. The following conditions warrant the use of this multiplex amplified probe technique:

  • COVID-19 Detection of SARS-CoV-2, the virus responsible for coronavirus disease (COVID-19), in patients exhibiting symptoms consistent with the illness.
  • Influenza Identification of influenza virus types A and B in patients who may be experiencing flu-like symptoms, allowing for differentiation from other respiratory infections.
  • Respiratory Syncytial Virus (RSV) Testing for RSV in patients, particularly in pediatric populations, where this virus can cause significant respiratory distress.

2. Procedure

The procedure for CPT® Code 87637 involves several critical steps to ensure accurate detection of the targeted viruses. The following outlines the procedural steps:

  • Sample Collection A respiratory sample is collected from the patient, which may include swabs from the nose or throat, or more invasive methods such as bronchoalveolar lavage. This sample is essential for the subsequent analysis.
  • Sample Preparation The collected sample undergoes treatment with various chemical solutions designed to remove fats and proteins, allowing for the extraction of RNA. This step is crucial for isolating both the patient's RNA and any viral RNA present.
  • Reverse Transcription An enzyme is added to the sample to convert the extracted RNA into DNA through a process known as reverse transcription. This step is necessary because the amplification process can only occur with DNA.
  • Probe and Primer Addition Oligonucleotide probes and primers, which are labeled with fluorescent dyes, are introduced to the sample. These probes specifically bind to the target nucleic acid sequences of the viruses being tested.
  • Amplification The prepared sample is placed in a real-time RT-PCR machine, where it undergoes a series of chemical reactions. The machine cycles through these reactions, doubling the amount of target DNA with each cycle, thereby amplifying the viral genetic material.
  • Fluorescence Measurement As the amplification occurs, the fluorescent markers attached to the newly created DNA copies emit signals that are measured in real time by the machine. This allows for the detection of the viruses present in the sample.
  • Confirmation of Presence When the fluorescence reaches a predetermined threshold, it confirms the presence of the virus(es) in the sample. The number of cycles required to reach this level of fluorescence can also provide insights into the severity of the infection.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87637, the results are analyzed and reported to the healthcare provider. The timely identification of the viruses allows for appropriate treatment decisions to be made, which may include antiviral medications or supportive care, depending on the diagnosis. Additionally, the results can inform public health measures, such as isolation protocols, to prevent the spread of infectious diseases. Patients may be monitored for symptoms and provided with guidance on follow-up care based on the test outcomes. It is essential to ensure that proper documentation of the procedure and results is maintained for compliance and billing purposes.

Short Descr SARSCOV2&INF A&B&RSV AMP PRB
Medium Descr IADNA SARSCOV2 & INF A&B & RSV MULT AMP PROBE TQ
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) Yes
APC Status Indicator Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) none
MUE 1
QW Clia waived test
GW Service not related to the hospice patient's terminal condition
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GZ Item or service expected to be denied as not reasonable and necessary
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
CC Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed)
GV Attending physician not employed or paid under arrangement by the patient's hospice provider
CR Catastrophe/disaster related
GA Waiver of liability statement issued as required by payer policy, individual case
HF Substance abuse program
77 Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
95 Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system.
CS Cost-sharing waived for specified covid-19 testing-related services that result in and order for or administration of a covid-19 test and/or used for cost-sharing waived preventive services furnished via telehealth in rural health clinics and federally qualified health centers during the covid-19 public health emergency
GC This service has been performed in part by a resident under the direction of a teaching physician
GF Non-physician (e.g. nurse practitioner (np), certified registered nurse anesthetist (crna), certified registered nurse (crn), clinical nurse specialist (cns), physician assistant (pa)) services in a critical access hospital
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
PD Diagnostic or related non diagnostic item or service provided in a wholly owned or operated entity to a patient who is admitted as an inpatient within 3 days
Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study
Q6 Service furnished under a fee-for-time compensation arrangement by a substitute physician or by a substitute physical therapist furnishing outpatient physical therapy services in a health professional shortage area, a medically underserved area, or a rural area
QJ Services/items provided to a prisoner or patient in state or local custody, however the state or local government, as applicable, meets the requirements in 42 cfr 411.4 (b)
SC Medically necessary service or supply
U7 Medicaid level of care 7, as defined by each state
XS Separate structure, a service that is distinct because it was performed on a separate organ/structure
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2023-01-01 Added First appearance of guideline addition in codebook.
2022-02-21 Changed Guidelines Added
2022-01-01 Added First appearance of code in codebook.
2022-01-01 Changed Short description changed.
2022-01-01 Note Grammar correction
2021-01-01 Added First appearance of code in CPT® Code Set.
2020-10-06 Added Code added.
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"